InMed Pharmaceuticals Provides Business Update and Milestones for 2024 [Yahoo! Finance]
InMed Pharmaceuticals Inc. - Common Shares (INM)
Company Research
Source: Yahoo! Finance
Actively seeking partnerships to advance INM-755 in Dermatology BayMedica subsidiary continues to focus on revenue growth and market expansion Vancouver, British Columbia--(Newsfile Corp. - January 16, 2024) - InMed Pharmaceuticals Inc . (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlines key accomplishments from 2023 and provides key strategic priorities for 2024. Eric A. Adams, InMed President and CEO, commented, "In 2023, we experienced significant progress in both InMed's pharmaceutical drug development and in BayMedica's health and wellness initiatives. Our primary accomplishments throughout the year included a number of key milestones, such as the completion of a Phase 2 clinical trial and the launch of two new preclinical programs targeting the treatment of Alzheimer's disease and Age-related Macular Degeneration ("AMD")." Adams continued, "As
Show less
Read more
Impact Snapshot
Event Time:
INM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INM alerts
High impacting InMed Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
INM
News
- InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board [Yahoo! Finance]Yahoo! Finance
- InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration [Yahoo! Finance]Yahoo! Finance
- InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies [Yahoo! Finance]Yahoo! Finance
- InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance [Yahoo! Finance]Yahoo! Finance
- InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
INM
Sec Filings
- 4/18/24 - Form 8-K
- 4/16/24 - Form 8-K
- 4/5/24 - Form 8-K
- INM's page on the SEC website